Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2019 | Current challenges in myeloma therapy

Karthik Ramasamy • 24 Mar 2019
EBMT 2019
Multiple Myeloma

Karthik Ramasamy, PhD, from Oxford University Hospitals, Oxford, UK, outlines the key challenges in treating myeloma currently. Dr Ramasamy was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Karthik Ramasamy

Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry 1:29
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy • 7 Dec 2025
Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial 1:55
Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial
Karthik Ramasamy • 15 Sep 2025
Updates on current research exploring treatment strategies for high-risk smoldering myeloma 2:14
Updates on current research exploring treatment strategies for high-risk smoldering myeloma
Karthik Ramasamy • 15 Sep 2025
The psychological impact of being diagnosed with MGUS: insights from the SECURE study 2:15
The psychological impact of being diagnosed with MGUS: insights from the SECURE study
Karthik Ramasamy • 15 Sep 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals